Linked Life Data

12424197

Source:http://linkedlifedata.com/resource/pubmed/id/12424197

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12424197rdf:typepubmed:Citationlld:pubmed
pubmed-article:12424197lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:12424197lifeskim:mentionsumls-concept:C0002895lld:lifeskim
pubmed-article:12424197lifeskim:mentionsumls-concept:C0439849lld:lifeskim
pubmed-article:12424197lifeskim:mentionsumls-concept:C0039730lld:lifeskim
pubmed-article:12424197lifeskim:mentionsumls-concept:C0445223lld:lifeskim
pubmed-article:12424197lifeskim:mentionsumls-concept:C0935850lld:lifeskim
pubmed-article:12424197lifeskim:mentionsumls-concept:C1552599lld:lifeskim
pubmed-article:12424197lifeskim:mentionsumls-concept:C1704787lld:lifeskim
pubmed-article:12424197pubmed:issue6lld:pubmed
pubmed-article:12424197pubmed:dateCreated2003-2-28lld:pubmed
pubmed-article:12424197pubmed:abstractTextAllogeneic bone marrow transplantation (BMT) from HLA-identical siblings is an accepted treatment for both thalassemia and sickle cell disease (SCD). However, it is associated with decided risk of both transplant-related mortality (TRM) and chronic graft-versus-host disease (GVHD). We analyzed 44 patients (median age, 5 years; range, 1-20 years) given an allogeneic related cord blood transplant for either thalassemia (n = 33) or SCD (n = 11). Thirty children were given cyclosporin A (CsA) alone as GVHD prophylaxis, 10 received CsA and methotrexate (MTX), and 4 patients received other combinations of immunosuppressive drugs. The median number of nucleated cells infused was 4.0 x 10(7)/kg (range, 1.2-10 x 10(7)/kg). No patient died and 36 of 44 children remain free of disease, with a median follow-up of 24 months (range, 4-76 months). Only one patient with SCD did not have sustained donor engraftment as compared with 7 of the 33 patients with thalassemia. Three of these 8 patients had sustained donor engraftment after BMT from the same donor. Four patients experienced grade 2 acute GVHD; only 2 of the 36 patients at risk developed limited chronic GVHD. The 2-year probability of event-free survival is 79% and 90% for patients with thalassemia and SCD, respectively. Use of MTX for GVHD prophylaxis was associated with a greater risk of treatment failure. Related CBT for hemoglobinopathies offers a good probability of success and is associated with a low risk of GVHD. Optimization of transplantation strategies could further improve these results.lld:pubmed
pubmed-article:12424197pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12424197pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12424197pubmed:languageenglld:pubmed
pubmed-article:12424197pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12424197pubmed:citationSubsetAIMlld:pubmed
pubmed-article:12424197pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12424197pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12424197pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12424197pubmed:statusMEDLINElld:pubmed
pubmed-article:12424197pubmed:monthMarlld:pubmed
pubmed-article:12424197pubmed:issn0006-4971lld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:LocatelliFran...lld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:BlattJulieJlld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:ReedWilliamWlld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:NaglerArnonAlld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:GarnierFederi...lld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:GluckmanElian...lld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:RobertsIreneIlld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:NugentDiane...lld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:KurtzbergJoan...lld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:VermylenChris...lld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:LutzPatrickPlld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:RochaVanderso...lld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:WoodardPaulPlld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:YanivIsaacIlld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:WillAndrew...lld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:HautPaul RPRlld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:GiorgianiGiov...lld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:MinieroRobert...lld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:RubinCharles...lld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:ErtemMehmetMlld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:LiXiaxinXlld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:WaltersMark...lld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:LubinBertram...lld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:BernaudinFran...lld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:GrafakosSteli...lld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:BrichardBened...lld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:BrochsteinJoe...lld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:RajaThirumala...lld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:TannoiaNunzia...lld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:IonescuIrinaIlld:pubmed
pubmed-article:12424197pubmed:authorpubmed-author:Eurocord...lld:pubmed
pubmed-article:12424197pubmed:issnTypePrintlld:pubmed
pubmed-article:12424197pubmed:day15lld:pubmed
pubmed-article:12424197pubmed:volume101lld:pubmed
pubmed-article:12424197pubmed:ownerNLMlld:pubmed
pubmed-article:12424197pubmed:authorsCompleteYlld:pubmed
pubmed-article:12424197pubmed:pagination2137-43lld:pubmed
pubmed-article:12424197pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:meshHeadingpubmed-meshheading:12424197...lld:pubmed
pubmed-article:12424197pubmed:year2003lld:pubmed
pubmed-article:12424197pubmed:articleTitleRelated umbilical cord blood transplantation in patients with thalassemia and sickle cell disease.lld:pubmed
pubmed-article:12424197pubmed:affiliationOncoematologia Pediatrica, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Università di Pavia, Italy. f.locatelli@smatteo.pv.itlld:pubmed
pubmed-article:12424197pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12424197pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:12424197pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12424197lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12424197lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12424197lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12424197lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12424197lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12424197lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12424197lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12424197lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12424197lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12424197lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12424197lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12424197lld:pubmed
More...